BioXcel Therapeutics, Inc.(BTAI)

$0.80—

Chart

BioXcel Therapeutics, Inc.(BTAI)

NASDAQ

$0.80—

Chart Studio

BTAI(BTAI)

BTAI

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.01

Nov 11, 2026 · Reports before open

Revenue Estimate

$191,394

FY2030E EPS$1.48

Analyst Sentiment

Wall St. Consensus

Hold

15 analysts·Moderate coverage

Score

8 Buy (53%)6 Hold (40%)1 Sell (7%)

Rating Breakdown

Strong Buy

00%

Buy

853%

Hold

640%

Sell

17%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.00

+24.4%

Consensus

$10.00

+1144.1%

Bull

$25.00

+3010.2%

12-Month Target Range15 analysts

$1.00$10.00$25.00

Current $0.80Consensus

Current Price

$0.80

Upside to Consensus

$9.20

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2598.40%

EPS—

FY2028

Rev+204.69%

EPS—

FY2029

Rev+182.46%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$769,915	$21M	$63M	$179M	$399M
Low	$578,699	$16M	$48M	$134M	$300M
High	$935,249	$25M	$77M	$217M	$485M
EBITDA Avg	$-461,949	$-12M	$-38M	$-107M	$-240M
Low	$-561,149	$-15M	$-46M	$-130M	$-291M
High	$-347,219	$-9M	$-29M	$-81M	$-180M
EBIT Avg	$-461,949	$-12M	$-38M	$-107M	$-240M
Low	$-561,149	$-15M	$-46M	$-130M	$-291M
High	$-347,219	$-9M	$-29M	$-81M	$-180M
Net Income Avg	$-33M	$-26M	$-9M	$-8M	$18M
Low	$-42M	$-34M	$-12M	$-10M	$12M
High	$-24M	$-18M	$-7M	$-5M	$23M
EPS Avg	$-2.70	$-2.14	$-0.79	$-0.62	$1.48
Low	$-3.45	$-2.81	$-1.01	$-0.79	$1.00
High	$-1.95	$-1.47	$-0.53	$-0.42	$1.89
Analysts (Rev / EPS)	1 / 1	2 / 2	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$191,394	$190,521	$800,000	$1M	$2M	$2M
Low	$191,394	$190,521	$800,000	$1M	$2M	$2M
High	$191,394	$190,521	$800,000	$1M	$2M	$2M
EBITDA Avg	$-114,836	$-114,312	$-480,000	$-780,000	$-900,000	$-1M
Low	$-114,836	$-114,312	$-480,000	$-780,000	$-900,000	$-1M
High	$-114,836	$-114,312	$-480,000	$-780,000	$-900,000	$-1M
EBIT Avg	$-114,836	$-114,312	$-480,000	$-780,000	$-900,000	$-1M
Low	$-114,836	$-114,312	$-480,000	$-780,000	$-900,000	$-1M
High	$-114,836	$-114,312	$-480,000	$-780,000	$-900,000	$-1M
Net Income Avg	$-31M	$-22M	$-9M	$-9M	$-8M	$-8M
Low	$-45M	$-22M	$-9M	$-9M	$-8M	$-8M
High	$-16M	$-22M	$-9M	$-9M	$-8M	$-8M
EPS Avg	$-1.01	$-0.72	$-0.31	$-0.29	$-0.26	$-0.26
Low	$-1.50	$-0.72	$-0.31	$-0.29	$-0.26	$-0.26
High	$-0.52	$-0.72	$-0.31	$-0.29	$-0.26	$-0.26
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Sep 23, 2024Mizuho Securities

Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI)

Target:$1.00

+69.8%from $0.59

Apr 15, 2024H.C. Wainwright

BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright

Target:$10.00

+244.8%from $2.90

Aug 15, 2023Mizuho Securities

Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy

Target:$4.00

+0.6%from $3.98

Jan 3, 2023H.C. Wainwright

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73

Target:$73.00

+239.9%from $21.48

Nov 11, 2022Guggenheim

Guggenheim Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $25

Target:$25.00

+68.7%from $14.82

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance